Impact Biomedical Inc (IBO) Actualités

DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth

ROCHESTER, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company...

Form 8-K - Current report

Form S-8 - Securities to be offered to employees in employee benefit plans

Impact BioMedical Inc. to Present at The Microcap Conference

HOUSTON, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering...

Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision

HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory Disease

HOUSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE: IBO), is thrilled to announce a...

Form 8-K - Current report

Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates

HOUSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering...

Impact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent Issue

HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (“IBO”) is pleased to announce that the US...

Impact BioMedical Inc. Introduces Leadership Team to Drive Innovation and Growth

NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering...

Form 8-K - Current report

Impact BioMedical Inc. Announces the Closing of its Initial Public Offering

NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) --  Impact BioMedical Inc. (NYSE American: IBO), a company...